Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAMEGA: Ziv-aflibercept + mFOLFOX6 in Advanced Esophagogastric Cancer
NCT01747551Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2013
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in esophageal cancer and gastric cancer (GC) comparing mFOLFOX6 + Ziv-aflibercept with mFOLFOX6 + Placebo (2 arms). Primary endpoint: Progression-free Survival at 6 months. Started Jan 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT01747551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01747551.